Semaglutide injection vials recalled over lack of sterility assurance
New Life Pharma is recalling one lot of Semaglutide Injection 2 mg sterile multi-dose vials for lack of assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Rubric level 3 covers risk-of-harm products where injury has not yet been reported: this is an FDA Class II recall of an injectable medicine whose sterility cannot be assured, with no injuries stated in the source.
Plain-English summary
New Life Pharma LLC is recalling Semaglutide Injection, 2 mg x 5, sterile multi-dose vial, prescription only, labelled for Nomida of Olathe, Kansas, NDC 84223-001-06. About 2 vials were distributed in Ohio. The FDA has classified this recall as Class II.
The recall was initiated for lack of assurance of sterility.
Affected product is lot 240903 with an expiry date of 9/30/2026.
Patients and prescribers can identify affected product by the NDC, lot number and expiry date above, and may contact New Life Pharma LLC for further information.
The recalled product
- Product
- Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06
- Manufacturer
- New Life Pharma LLC
- Category
- Drug — Injectable
- Affected units
- 2
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot 240903
- exp 9/30/2026
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 4 recalled by New Life Pharma LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · New Life Pharma LLC
See all →- HighTirzepatide injection 15 mg vials recalled over sterility assurance failure
FDA (Drugs) · 2026-03-11
- HighTirzepatide injection vials recalled over lack of sterility assurance
FDA (Drugs) · 2026-03-11
- HighSemaglutide injection multi-dose vials recalled over lack of sterility assurance
FDA (Drugs) · 2026-03-11
Same hazard · sterility failure
See all →- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22
Similar recalls
- HighSemaglutide 5 mg vials recalled for lack of sterility assurance
FDA (Drugs) · 2025-11-05
- HighSemaglutide 6 mg vials recalled for lack of sterility assurance
FDA (Drugs) · 2025-11-05
- HighSemaglutide 2.5 mg vials recalled for lack of sterility assurance
FDA (Drugs) · 2025-11-05
- HighSemaglutide 10 mg vials recalled for lack of sterility assurance
FDA (Drugs) · 2025-11-05
- HighCompounded semaglutide vials recalled for lack of sterility assurance
FDA (Drugs) · 2025-11-05
- HighSemaglutide 8 mg vials recalled for lack of sterility assurance
FDA (Drugs) · 2025-11-05